RSS

  • Redwood Pharma acquires intellectual property rights

    Redwood Pharma has entered into an agreement regarding the acquisition of certain patent and patent applications, as well as clinical and preclinical data. Payment will occur through the issuance of 525,000 shares by Redwood Pharma. CapaVision Ltd is a small company based in England that develops medicines in ophthalmology. CapaVision has led a development program […]

  • Positive meeting with Medical Products Agency prior to clinical Phase II trial

    Redwood Pharma has met with the Swedish Medical Products Agency in an advisory discussion. The meeting gave the company the opportunity to present its development and clinical plans for RP101, which will be tested in a clinical Phase II study in women suffering from chronic dry eye disease. The meeting gave Redwood Pharma the opportunity […]

  • Additional US patent to be granted regarding IntelliGel

    The United States Patent and Trade Mark Office (USPTO) has communicated its intention to grant a new US patent in the portfolio licensed to Redwood Pharma from Broda International LLC. A new US patent will, when granted, provide enhanced patent protection in the United States for the so-called IntelliGel platform, which is used, inter alia, […]

  • Redwood Pharma to Attend ARVO in Honolulu, April 30 – May 3, 2018

    Redwood Pharma will attend the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii to meet with prospective commercialization partners for RP101, the Company’s unique treatment for chronic dry eye disease in postmenopausal women. ARVO’s Annual Meeting is arguably the largest conference that brings together 11,000 international basic and clinical researchers […]

  • Redwood Pharma to Attend BIO-Europe 2018, Mar. 11 – 14 in Amsterdam for Partnering Discussions

    Redwood Pharma will be attending BIO-Europe 2018 in Amsterdam, Mar. 11 – 14 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform. RP101 is the Company’s lead program for the development […]

  • Interview with CEO: Development throught toxicology and safety studies

    CEO Martin Vidaeus explains about development through toxicology and safety studies. About RP101 RP101 is the company’s main development program of a new treatment of chronic dry eye disease in postmenopausal women. The active substance is a molecule that has already shown safety and efficacy in two clinical phase II studies conducted in the United […]

  • Redwood Pharma starts production of RP101 for clinical trials

    Following successfully completed toxicology and safety studies, Redwood Pharma has now started production of the drug RP101 for use in the forthcoming Phase II clinical trial. This is another important milestone in the development of RP101, the first therapy for treatment of moderate to severe dry eye in postmenopausal women. Production of material for the […]

  • Toxicology and Safety Studies are Successfully Completed

    Redwood Pharma AB (publ) announces that the RP101 toxicology studies are now successfully completed. The Company can thereby continue the development of RP101 and approach the next goal of starting the clinical Phase II study in patients with chronic dry eye disease. Safety studies are a critical step in the development of a pharmaceutical. Redwood […]

  • Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions

    Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 – 8 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform. RP101 is the Company’s lead program for the development […]

  • Redwood Pharma enters into agreement with CRO for clinical trial

    Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical phase II trial in patients with chronic dry eye disease. The clinical trial will be performed in Europe where CROss Alliance is well-established and has earlier successfully executed several studies within ophthalmology. The agreement with […]